Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Amgen (NQ: AMGN )

321.66 +0.33 (+0.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,552,128
Open 320.61
Bid (Size) 321.06 (7)
Ask (Size) 324.48 (1)
Prev. Close 321.33
Today's Range 319.18 - 322.56
52wk Range 249.70 - 346.85
Shares Outstanding N/A
Dividend Yield 2.65%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is Amgen Stock a Buy?
This biotech leader could be poised to rally higher. 
Via The Motley Fool
Looking Into Amgen's Recent Short Interest
Via Benzinga

Performance

YTD
+8.16%
+8.16%
1 Month
-3.38%
-3.38%
3 Month
-2.91%
-2.91%
6 Month
+19.61%
+19.61%
1 Year
+14.63%
+14.63%

More News

Read More
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
Via Investor's Business Daily
In-Depth Examination Of 11 Analyst Recommendations For Amgen
Via Benzinga
Blue Skies, New Highs Remain Disciplined And Do Not Chase Extended Ideas
Via Talk Markets
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Via Benzinga
(AMGN) - Analyzing Amgen's Short Interest
Via Benzinga
Analyst Expectations For Amgen's Future
Via Benzinga
2 Top Dividend Stocks to Buy Hand Over Fist Right Now
Via The Motley Fool
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
Via Benzinga
Topics Stocks
Exposures US Equities
Deere, Amgen, Copart And More: CNBC's 'Final Trades'
Via Benzinga
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Via Benzinga
2 Biotech Stocks to Buy Hand Over Fist in October
Via The Motley Fool
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
Via The Motley Fool
3 Magnificent Dividend Stocks to Buy in October
Via The Motley Fool
Should You Buy the Dip on This Top Growth Stock?
Via The Motley Fool
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Via Investor's Business Daily
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Federal Judge Rules Amgen Must Face Tax Liability Lawsuit That Alleges Reckless Concealment Of $10.7B Tax Bill
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
AskSlim Market Week - Friday, Sep. 27
Via Talk Markets
Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
Via Benzinga
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
Via Benzinga
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
Via Investor's Business Daily
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.